LTGO Latigo Biotherapeutics, Inc.

Fundamentals / CIK 0002056611 / USD

Latigo Biotherapeutics, Inc. reported $408.5M in total assets through September 30, 2026 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open LTGO in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

No annual income statement rows are available in SEC EDGAR CompanyFacts for LTGO.

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Research & Development $17.50M $21.23M -- $22.10M $22.92M --
Total Operating Expenses $22.93M $25.81M -- $24.72M $25.75M --
Operating Income -$22.93M -$25.81M -- -$24.72M -$25.75M --
EBITDA -$22.83M -$25.71M -- -$24.62M -$25.64M --
Interest Expense $699K $251K -- $0 $0 --
Income Tax Expense $0 $0 -- $0 $0 --
Net Income -$20.95M -$25.80M -$22.96M -$24.80M -$25.84M -$20.95M
Basic EPS -$0.55 -$27.59 -- -$29.50 -$36.52 --
Diluted EPS -$0.55 -$27.59 -- -$29.50 -$36.52 --
Basic Shares Outstanding 37.8M 935.0K -- 840.4K 707.5K --
Diluted Shares Outstanding 37.8M 935.0K -- 840.4K 707.5K --

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

No annual balance sheet rows are available in SEC EDGAR CompanyFacts for LTGO.

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2026-06-30 2025-12-31
Cash & Cash Equivalents $401.2M $55.00M $69.44M
Cash & Short-Term Investments $401.2M $55.00M $69.44M
Total Current Assets $406.4M $59.20M $73.83M
Property, Plant & Equipment, Net $440K $457K $446K
Other Non-Current Assets $433K $3.80M $616K
Total Non-Current Assets $2.01M $5.56M $1.69M
Total Assets $408.5M $64.76M $75.52M
Accounts Payable $5.08M $3.57M $5.01M
Total Current Liabilities $13.96M $51.58M $18.45M
Other Non-Current Liabilities $35K $35K $35K
Total Non-Current Liabilities $518K $683K $162K
Total Liabilities $14.48M $52.26M $18.61M
Total Debt (incl. Leases) $1.19M $1.35M $690K
Common Stock $7.0K $0 $0
Retained Earnings -$312.8M -$291.9M -$243.1M
Total Stockholders' Equity $394.0M -$276.1M -$231.7M
Total Equity $394.0M -$276.1M -$231.7M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

No annual cash flow statement rows are available in SEC EDGAR CompanyFacts for LTGO.

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Net Income -$20.95M -$25.80M -$22.96M -$24.80M -$25.84M -$20.95M
Depreciation & Amortization $100K $100K -- $100K $100K --
Stock-Based Compensation $2.54M $2.14M -- $1.82M $1.68M --

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

No annual ratios & growth rows are available in SEC EDGAR CompanyFacts for LTGO.

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Current Ratio 29.11x 1.15x -- -- -- --
Quick Ratio 28.73x 1.07x -- -- -- --
Debt to Equity 0.00x -- -- -- -- --
Source: SEC EDGAR CompanyFacts (CIK 0002056611) · from March 31, 2025 Data through September 30, 2026 · synced Nov 20, 2026, 05:32 UTC · Open in terminal